UNSPSC 51392903: Azanator maleate

This classification denotes a bronchodilator with the molecular formula C18H18N2O.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63ISF1PDWX. The term azanator maleate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule azanator maleate under HS 29349990 and SITC 51579. As of Q4 2014, AZANATOR MALEATE remains US FDA's Preferred Term for this commodity. Azanator maleate bears US NLM identifiers UMLS ID C2698286 and NCI Concept Code C74219.

SMILES: CN1CCC(=C2C3CCCCC3OC4C2CCCN4)CC1.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51392903 Azanator maleate, a Commodity code, shows minimal recent activity aligned with its nominal pharmaceutical scope. The two recent state and local opportunities posted under this code involve naloxone procurement and direct-to-manufacturer prescription programs—neither of which centers on azanator maleate itself. Seminole County, Florida's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives, with quarterly deliveries and fixed-fee pricing. Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription contracting models rather than procuring a specific pharmaceutical product. The code appears to reflect a tagging mismatch between the UNSPSC category and the actual work being bought; recent solicitations focus on opioid-reversal agents and pharmacy benefit program design rather than azanator maleate as a distinct product line.

Activity under this code is geographically sparse and project-based. The two solicitations originate from Florida and Texas health agencies. Seminole County's procurement required competitive bidding through electronic submission, E-Verify compliance, drug-free workplace certification, and potential FEMA funding with federal compliance obligations. The Texas RFI operated as an exploratory information-gathering vehicle with no formal award value, set-asides, or binding timeline—typical of preliminary market research before formal RFP issuance. Neither opportunity included explicit set-aside designations for disadvantaged enterprises. Given the limited volume of recent solicitations and the apparent mismatch between the code name and the products actually being procured, this code warrants close monitoring rather than immediate pursuit; activity may accelerate if state health agencies formalize pharmacy benefit contracting, but current signals suggest the code sees little regular demand.